Enhancing cognition in bipolar disorder

ISRCTN ISRCTN93360820
DOI https://doi.org/10.1186/ISRCTN93360820
Protocol serial number 2005/165: version 2
Sponsor Suffolk Mental Health Partnership NHS Trust (UK)
Funder Suffolk Mental Health Partnership NHS Trust (UK)
Submission date
16/05/2007
Registration date
16/07/2007
Last edited
24/02/2015
Recruitment status
Stopped
Overall study status
Stopped
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Judy Rubinsztein
Scientific

Wedgwood House
West Suffolk Hospital
Hardwick Lane
Bury St Edmunds
IP4 5PD
United Kingdom

Study information

Primary study designInterventional
Study designDouble-blind placebo-controlled cross-over study
Secondary study designRandomised cross over trial
Study type Participant information sheet
Scientific titleEnhancing cognition in bipolar disorder
Study objectivesPatients with bipolar affective disorder, currently in remission, will show enhanced cognition on tests of attention, executive function and memory after taking a single dose of modafinil compared with performance on the placebo.
Ethics approval(s)Suffolk Local Research Ethics Committee, 19/08/2005, LREC number: 05/Q0102/71
Health condition(s) or problem(s) studiedBipolar disorder
InterventionParticipants will be randomized to oral administration of one dose of modafinil (200 mg) or one dose of placebo (double blind). After a minimum of one-week washout period a cross-over intervention will be carried out. The interventions started in July 2006.

Updated 24/02/2015: the trial was stopped due to poor recruitment.
Intervention typeDrug
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Modafinil
Primary outcome measure(s)

Performance on tests of attention, memory and executive function, assessed 2 hours after taking the drug/placebo by the following:

Symptom Rating Scales:
1. Hamilton depression scale
2. Young mania scale
3. Beck depression inventory
4. Apathy scale
5. Epworth sleepiness scale
6. Bond and Lader scale

Neuropsychological Tests: (CAmbridge Neuropsychological Test Automated Battery). [CANTAB])
7. Digit Span
8. Controlled oral word association test
9. Motor Screening
10. Pattern recognition memory test
11. Spatial recognition memory test
12. Big/ little circle
13. Rapid visual information processing task
14. Rey auditory verbal learning test
15. Attentional set shifting task
16. One Touch Tower of London task

All tests will be carried out on both testing sessions (one week apart).

Key secondary outcome measure(s)

No secondary outcome measures

Completion date01/08/2008
Reason abandoned (if study stopped)Participant recruitment issue

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexAll
Target sample size at registration20
Key inclusion criteria1. All patients must be able to give informed written consent to participate in the study
2. Aged 18 to 65
3. English should be spoken fluently
4. Participants should be literate and have normal or corrected to normal eyesight
5. All patients must have met Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM IV) criteria for Bipolar I disorder in the past i.e. they must have had an episode of mania or a mixed affective state
6. The Hamilton Depression Rating Scale and Young Mania Scale scores must both be less than eight
Key exclusion criteria1. Patients who currently fulfill criteria for mania, a mixed affective state, hypomania or major depression
2. Patients who score less than or equal to 24 on the Mini-Mental State Examination (MMSE). All patients with a diagnosis of dementia will be excluded after review of case-records and/or discussion with their clinician
3. Current diagnosis of alcohol or drug dependence based on DSM IV criteria
4. History of learning disability (or Wechsler test of Adult Reading score <90) or dyslexia
5. Any known neurological illness (including narcolepsy)
6. Unstable medical illness that may affect cognition (untreated thyroid disease, type I diabetes mellitus or current treatment with steroids)
7. Have received electroconvulsive therapy in the past three months
8. Patients taking herbal remedies such as St John’s Wort or Gingko Biloba
9. Moderate or severe hypertension. All patients should have blood pressure measurements within normal limits (i.e. systolic blood pressure less than or equal to 160 and diastolic blood pressure less than or equal to 90) prior to drug administration
10. Known history of angina or cardiac arrhythmias
11. Pregnant or breastfeeding
12. Patients taking phenytoin (due to possible increase in plasma concentration)
13. Known hypersensitivity to modafinil or its excipients, or to the placebo
14. Participated in another clinical drug trial within the last three months
15. Female patients on an Oral Contraceptive (OC) will need to be counselled about the possibility that modafinil may reduce the effectiveness of the OC. They will only be excluded if they are not willing to take the family planning advice recommendations in the British National Formulary (BNF) (for the short term course of an enzyme inducing drug)
16. Patients who have had any changes to their psychotropic drugs over the past six weeks
Date of first enrolment01/08/2005
Date of final enrolment01/08/2008

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

West Suffolk Hospital
Bury St Edmunds
IP4 5PD
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes
BMC - Part of Springer Nature Springer Nature